Umezaki 2016.

Methods	Single‐centre, placebo‐controlled, single‐blinded parallel RCT
Participants	26 BMS patients Mean age 63.9 years (SD 9.56) Sex: 24F:2M (F92%:M8%) Inclusion/exclusion and diagnostic criteria appropriate
Interventions	Intervention category: Electromagnetic radiation Group 1: (n = 14) High‐frequency transcranial magnetic stimulation (TMS): 10 daily sessions (1 session p/day for 5 days, 2 days untreated and then a further 5 days of 1 session p/day) totalling 30,000 single‐pulse stimulations at 10 Hz (MagVenture MagPro x100 Stimulator ‐ MagVenture Inc., Denmark; Cool‐B65 A/P figure 8 coil, positioned over left dorsolateral prefrontal cortex (DLPFC) at medial frontal 10‐20 system EEG‐electrode location (F3); unconnected ECT electrodes placed under coil ‐ Natus Neurology, Middleton, Wisconsin) Group 2: (n = 12) Placebo: 10 daily sessions (1 session p/day for 5 days, 2 days untreated and then a further 5 days of 1 session p/day) totalling 30,000 single‐pulse stimulations (MagVenture MagPro x100 Stimulator ‐ MagVenture Inc., Denmark; shielded Cool‐B65 A/P figure 8 coil, positioned over left DLPFC at location F3; connected ECT electrodes placed under coil to stimulate when TMS was triggered ‐ Natus Neurology, Middleton, Wisconsin) Duration: 2 months
Outcomes	Pain intensity at baseline, daily during days 1‐14, follow‐up at day 15, 1 month and 2 months (assessed by VAS) Functional impairment at baseline, days 8 and 15, 1 month and 2 months (assessed by Short Form McGill Pain Questionnaire (SFMPQ); Brief Pain Inventory (BPI); Patient Health Questionnaire (PHQ‐9); Patients' Global Impression of Change (PGIC); Clinical Global Impression for global improvement scale (CGI‐I)) Adverse effects Outcomes not of interest to this review Patients' assumed treatment group (TMS or placebo; assessed at end of treatment)
Source of funding	Not reported
Notes	No numbers (tables 1‐3), means or SDs (text and figures 2‐3) associated with the study's results were available in the published study paper. Until this information is obtained we are unable to incorporate this study within our analyses Quotation: "SSRIs were prescribed for around 40% of the patients, but these did not adequately relieve the BMS pain. Although 30% of the patients had a prior history of depression, none currently met diagnostic criteria for depression" Comment: Unclear if SSRIs were prescribed before the trial commenced, or during the trial as a co‐intervention SES: Not reported Conflict of interests: Not reported Data analysis: Per‐protocol (according to Figure 1). 6 participants did not complete the assigned intervention duration due to competing commitments which allowed them to attend only 2 sessions (of 10 scheduled) each. Group 1: 2 patients abandoned study; Group 2: 4 patients left study

BMS = burning mouth syndrome; F = female; M = male; QoL = quality of life; RCT = randomised controlled trial; SD = standard deviation; SES = socioeconomic status; SSRIs = selective serotonin reuptake inhibitors; VAS = visual analogue scale.